Annexon, Inc. (NASDAQ:ANNX) EVP Sells $31,950.00 in Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Ted Yednock sold 4,500 shares of the business’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $7.10, for a total transaction of $31,950.00. Following the completion of the transaction, the executive vice president now owns 71,365 shares in the company, valued at $506,691.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Ted Yednock also recently made the following trade(s):

• On Thursday, September 5th, Ted Yednock sold 5,500 shares of Annexon stock. The stock was sold at an average price of $5.64, for a total value of $31,020.00.
• On Thursday, August 29th, Ted Yednock sold 5,500 shares of Annexon stock. The shares were sold at an average price of $5.95, for a total value of $32,725.00.

Annexon Stock Performance

NASDAQ:ANNX opened at $7.03 on Monday. The stock’s fifty day moving average price is $6.05 and its two-hundred day moving average price is $5.58. Annexon, Inc. has a 52-week low of $1.57 and a 52-week high of $8.40. The company has a market cap of $649.66 million, a price-to-earnings ratio of -4.78 and a beta of 1.28.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). On average, equities analysts predict that Annexon, Inc. will post -0.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ANNX. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a report on Monday, September 9th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Annexon in a report on Tuesday, August 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $16.00 price objective on shares of Annexon in a research report on Tuesday, August 13th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Annexon currently has an average rating of “Buy” and a consensus price target of $15.80.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ANNX. Ameritas Investment Partners Inc. lifted its stake in shares of Annexon by 78.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock valued at $48,000 after purchasing an additional 2,949 shares during the period. Sandia Investment Management LP acquired a new position in shares of Annexon in the 2nd quarter valued at $49,000. Victory Capital Management Inc. acquired a new position in shares of Annexon in the 2nd quarter valued at $51,000. Principal Financial Group Inc. acquired a new position in shares of Annexon in the 2nd quarter valued at $56,000. Finally, Comerica Bank acquired a new position in shares of Annexon in the 1st quarter valued at $72,000.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.